Phase 3 randomized-controlled trials evaluating efficacy and safety of subcutaneous efgartigimod PH20 using pre-filled syringes in patients with Graves’ disease inadequately controlled with antithyroid drugs: Trials in Progress

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) - argenx

https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-11-02

Kristien Boelaert 1; Chrysoula Dosiou 2; Tomasz Bednarczuk 3; Colin Dayan 4; Kris Vande Walle 5; Kelly Hogan 5; Ivaylo Stoykov 6; Miloš Žarković 7; Mario Salvi 8

Sep 9, 2026